The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.
EUDRACT Number: 2013-000277-72
Study sites
- Centre Hospitalier Emile Mayrisch, Differdange
- Centre Hospitalier Regional de la Citadelle, Liège
- CHA de l’Ardenne, Libramont
- CHC Clinique Saint-Joseph, Liège
- Clinique et maternité St. Elizabeth, Namur
- Cliniques Universitaires St. Luc, Bruxelles
- GZA Sint Augustinus, Wilrijk
- UZ Antwerpen, Edegem
- UZ Gent, Gent
- UZ Leuven, Leuven
